A single dose of a bispecific nanobody has protected mice from SARS-CoV, SARS-CoV-2 and MERS-CoV, Georgia State University said on 18 November 2026, describing a study published online on 16 November in ACS Nano.
The construct, named 3B11-1C11-Fc, “neutralized all tested SARS-CoV, SARS-CoV-2 and MERS-CoV viral strains,” the university said, “remained highly stable across a range of pH and temperature conditions, and was produced at a high yield in mammalian cells.” In mouse models, “a single dose of this nanobody significantly reduced viral loads and protected the animals from SARS-CoV, SARS-CoV-2 and MERS-CoV infections, with no apparent weight loss or severe clinical symptoms in most treated animals.” Those results are from mice and laboratory assays. The announcements describe no human trials and give no development timetable.
In brief
- A Georgia State-led team, with US academic partners, reports a bispecific nanobody that bound the receptor-binding domains of all three highly pathogenic human coronaviruses and neutralised every strain tested in the study.
- In mice, a single dose reduced viral loads and protected the animals from all three viruses, with no apparent weight loss or severe symptoms in most of those treated.
- The work is funded by NIH institutes. It has not been tested in people, and no timeline for that step has been given.
Two smaller binders were joined to cover all three viruses
Nanobodies, also called single-domain or VHH antibodies, are small fragments taken from heavy-chain-only antibodies. Georgia State says they are about one-tenth the size of conventional antibodies, are highly stable, have “cost-effective production,” and can reach hidden regions of viral proteins that larger antibodies miss. From immunised phage display libraries, the researchers found fragments that bound the receptor-binding domains, or RBDs, of the three viruses — the part of the spike used to latch onto human cells.
Nanobody 3B11 bound the RBDs of both SARS-CoV and SARS-CoV-2 and, the university says, neutralised diverse prototypic strains and variants of those two viruses. Nanobody 1C11 neutralised all MERS-CoV strains tested, and an Fc-fused version, in which the fragment is attached to a segment of a human antibody, “substantially enhanced potency.” The nanobodies worked by blocking the interaction between the viral RBDs and the receptors the viruses use to enter cells. Cryo-electron microscopy, computational modelling and epitope mapping were used to show the sites the fragments recognise.
The team then built the bispecific nanobody 3B11-1C11-Fc so that one molecule would bind all three RBDs. That is the construct tested in the mouse experiments. Lanying Du, a distinguished university professor in Georgia State’s Institute for Biomedical Sciences and a corresponding author, said: “Our goal was to develop a single therapeutic that could address all three highly pathogenic coronaviruses.” “This bispecific nanobody binds and neutralizes SARS-CoV, SARS-CoV-2 and MERS-CoV, and protected mice against all three highly pathogenic human coronaviruses, showing its promise for further therapeutic development.”
The study was funded by the National Institute of Allergy and Infectious Diseases and the National Institute of General Medical Sciences, both part of the US National Institutes of Health. Georgia State led the work with collaborators at Iowa State University, the University of Iowa, Johns Hopkins University School of Medicine, the University of Minnesota Medical School and the Wistar Institute. Yang Yang of Iowa State and Stanley Perlman of the University of Iowa are named as co-corresponding authors.
A protected mouse is still a long way from a patient
Du’s “promise for further therapeutic development” is the right scale of claim, because the public account stops at animals and the bench. The mouse result is not trivial: a single dose, three viruses, lower viral loads, and no apparent weight loss or severe symptoms in most treated animals is a broader animal package than many early antiviral papers can show. It is still an animal package. “Most treated animals” leaves room for exceptions, and nothing in the university note or the paper’s public description names a first-in-human study, a dose for people, or a date by which one might start.
That limit matters for readers who have watched other laboratory antivirals travel slowly, or not at all, into the clinic. TSN has already covered a Cambridge bird-flu vaccine that protected animals in trials, another early-stage result that has to be kept in its animal setting, and a structural map of how Andes hantavirus latches onto human cells, which explains a viral entry step without itself being a medicine. A DNA nanoswitch platform for screening protein-protein drug leads is a closer neighbour in method than in disease: a tool for finding candidates, not a finished drug. 3B11-1C11-Fc sits in that same early band. High yield in mammalian cells “could support large-scale manufacturing,” Georgia State says; that is a production note, not evidence that manufacturing has been organised.
The next facts that would change the picture are ordinary and specific: a stated plan for human testing, a safety study in a second species, or a named development partner. Until those appear, the accurate description is the one the authors have already used. A bispecific nanobody has neutralised all tested strains of the three deadliest human coronaviruses and protected mice. It is not yet a treatment for people.
Sources
- Georgia State University, “Therapeutic Antibody Protects Against All Three Pathogenic Human Coronaviruses, Study Finds,” 18 November 2026
- Shengnan Qian, Yu Li, Abhishek K. Verma, Abhijeet Roy et al., “Bispecific Nanobody Broadly Neutralizes and Cross-Protects against Three Highly Pathogenic Human Coronaviruses,” ACS Nano, published online 16 November 2026
Get TSN’s biggest tech stories, explained.
News and insights across AI, tech, crypto and cybersecurity. Every source linked. Unsubscribe anytime.
Get the newsletterRelated stories
DNA Nanoswitch FIND Platform Screens PPI Drug Leads is the closest TSN neighbour on early drug-lead work, and the right next stop for readers asking how a laboratory binder becomes a candidate.
- Cambridge AI Bird Flu Vaccine Protects Animals in Trials is the nearer comparison for an animal protection result that has not yet been shown in people.
- Scientists Map How Andes Hantavirus Latches Onto Human Cells explains another viral entry step at the receptor, without claiming a therapy.
Follow @tsnmediahub on X for breaking AI news as it happens.
Follow on X
